---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-260924"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:06:06.049359+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TuHURA secures $3M bridge loan at 3% monthly interest, secured by ImmuneFx patents

## Summary
- Initial $1.5M advance from Matthew Nachtrab Revocable Trust on Oct 27, 2025; up to $3M total available.
- Interest at 3% per month (36% annual); $180K loan fee plus warrants covering 10% of each advance.
- Loan secured by first-priority lien on U.S. patents for ImmuneFx technology platform.
- Maturity Dec 31, 2025 or 30 days after an equity raise >$12M; proceeds for working capital.
- Prepayment allowed without penalty; lender may fund additional $1.5M upon written request.

## SEC filing metadata
- accession: 0001193125-25-260924
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312525260924/0001193125-25-260924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312525260924/hura-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-260924
- JSON: https://secwatch.observer/filing/0001193125-25-260924.json
- Plain text: https://secwatch.observer/filing/0001193125-25-260924.txt

## Key facts
- Debt Financings
  TuHURA Biosciences, Inc./NV incurred loan of up to $3,000,000 with Matthew Nachtrab Revocable Trust dated 12/18/2014 at 3% per month maturing the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash.
  - Instrument: loan
  - Principal: up to $3,000,000
  - Counterparty: Matthew Nachtrab Revocable Trust dated 12/18/2014
  - Rate: 3% per month
  - Maturity: the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash
  - Event: incurrence
  source text: Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000119312525260924/0001193125-25-260924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.